Arix Bioscience
Arix Bioscience is a venture capital firm that develops, sources and finances healthcare and life science startups.
Business Model:
Revenue: $647.6k
Employees: 11-50
Rankings
Industries / Tags:
Detailed Arix Bioscience Information
Geographic Data
Address: 20 Berkeley Square
City: London
State: england
Zip: W1J 6EQ
Country: GB
Financial Info
Stage:
post ipo equity
Raised Last:
$21M
Raised Total:$21M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Arix Bioscience is a venture capital firm that develops, sources and finances healthcare and life science startups.
Contact Phone:
Contact Email:
Arix Bioscience went public on 2/17/2017 on the London Stock Exchange
Listed Exchange:
London Stock Exchange
IPO Date:
2/17/2017
IPO Valuation:
$232M
Ticker Symbol:
ARIX
IPO Price:
$2.569181734234905/share
Amount Raised:
$124M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2017 | PreciThera | Series A | 28.7M |
| 12/2021 | Depixus | Series A | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 9/2016 | Artios Pharma | Series A | 0 |
| 1/2018 | Quench Bio | Seed Round | - |
| 5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
| 12/2017 | Atox Bio | Series F | 0 |
| 6/2017 | Mitoconix Bio | Series A | 20M |
| 6/2017 | LogicBio Therapeutics | Series B | 45M |
| 3/2019 | Imara | Series B | 0 |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 10/2018 | VelosBio | Series A | 58M |
| 1/2020 | Quench Bio | Series A | 50M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 8/2017 | Amplyx Pharmaceuticals | Series C | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 9/2017 | Autolus | Series C | 80M |
| 4/2023 | Evommune | Series B | 50M |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 9/2019 | STipe Therapeutics | Series A | 21.8M |
| 3/2016 | Autolus | Series B | 56.7M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 12/2021 | Sorriso Pharmaceuticals | Series A | 0 |
| 4/2023 | Evommune | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 12/2021 | Sorriso Pharmaceuticals | Series A | 0 |
| 12/2021 | Depixus | Series A | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 3/2021 | Pyxis Oncology | Series B | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
